Latest Articles
Oriva: Targeting the endometriosis trifecta - BioCentury
Oriva: Targeting the endometriosis trifecta BioCentury
Published: July 16, 2026, 12:14 a.m.
New reporting tool targets maternal-fetal teams as pregnancy complexity rises - FemTech World
New reporting tool targets maternal-fetal teams as pregnancy complexity rises FemTech World
Published: July 9, 2026, 1:46 p.m.
Xella targets to fill the gaps in women’s diagnostics with AI - Longevity.Technology
Xella targets to fill the gaps in women’s diagnostics with AI Longevity.Technology
Published: June 29, 2026, 5:01 p.m.
H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright raises Absci stock price target on trial data By Investing.com Investing.com South Africa
Published: June 25, 2026, 5:39 p.m.
H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com Australia
H.C. Wainwright raises Absci stock price target on trial data By Investing.com Investing.com Australia
Published: June 25, 2026, 5:15 p.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com
Published: June 24, 2026, 11:25 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology
Published: June 19, 2026, 5:05 p.m.
'If you hate this country, leave': Hanson makes fiery Press Club debut with familiar targets in her sights - psnews.com.au
'If you hate this country, leave': Hanson makes fiery Press Club debut with familiar targets in her sights psnews.com.au
Published: June 18, 2026, 4:17 a.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - riauone.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 riauone.com
Published: June 15, 2026, 12:29 p.m.
Link copied to clipboard!